Bristol Myers Squibb Shares Surge 54.57% in Volume, Ranked 160th in Daily Trading

On May 27, 2025, Bristol Myers Squibb (BMY) saw a significant surge in trading volume, with a total of 6.08 billion shares exchanged, marking a 54.57% increase from the previous day. This substantial trading activity placed BMY at the 160th position in terms of daily trading volume among all stocks.

Bristol Myers Squibb Canada announced that Health Canada has approved a new subcutaneous formulation of OPDIVO® (nivolumab for subcutaneous injection) for use across all currently authorized solid tumor indications. This new formulation is administered every two, three, or four weeks and is not to be used concurrently with YERVOY®. The approval of this new formulation provides an additional treatment delivery method, offering clinicians and patients flexibility and convenience across multiple tumor types, including melanoma, renal cell carcinoma, gastric cancer, and other solid tumors.

This new subcutaneous option of OPDIVO® is designed to reduce administration time for eligible patients, potentially easing the demand on infusion chairs and allowing patients to spend less time at the clinic. This is particularly beneficial in settings where capacity is limited or patient volumes are high. The approval represents a meaningful advancement for patients with solid tumors and the teams that care for them, offering added convenience to patients and facilitating the administration of immunotherapy, especially in the maintenance phase of treatment plans.